Lymphatic System Health in Alzheimer's Disease
Key facts
- Who runs it
- Neurological Associates of West Los Angeles
- Where
- Los Angeles and Santa Monica, United StatesSee the 2 sites
- Trial code
- Status
- Withdrawn
- Phase
- Phase 1
- Started
- 10 Dec 2021
- Ended
- Dec 2023
- Type of study
- Interventional
- Treatments tested
- Dexmedetomidine
- Record updated
- 28 September 2022
- Why it stopped
- Pending COVID-19 pandemic
Who can take part
- Age
- 18 years to 90 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- In order for a subject to be considered for this study, the subject must be willing to comply with the study protocol. They must be between 18 and 90 years old. They must complete neurocognitive testing to assess cognitive impairment (QDRS and RBANS)
Who cannot take part
- Advanced stages of any terminal illness or any active cancer that requires chemotherapy
- Hepatic impairment
- Cardiovascular, cerebrovascular, and peripheral vascular arterial thrombosis
- Significant cytopenia
- Women who are pregnant, may become pregnant, or are breastfeeding
- Any counter indications to dexmedetomidine
- Subjects unable to give informed consent or in vulnerable categories, such as prisoners
Where in United States
- Westwood Open MRILos Angeles, United States
- Neurological Associates of West Los AngelesSanta Monica, United States
About the trial
What the trial wants to find out
This study hopes to investigate differences in lymphatic health of patients with Alzheimer's disease by analyzing diffusion-weight images in conscious and sleep states. Dexmedetomidine is a short-acting agent that facilitates a sedated state characterized by slow waves and inhibition of norepinephrine. Conceptually, dexmedetomidine may be preferred to other agents, because it is a short-acting norepinephrine blocker, which could mimic slow wave sleep architecture, opening interstitial spaces, and facilitating plaque removal. Dexmedetomidine may also be preferred given its safety profile among the elderly and acutely ill compared to other anesthetic agents. Sleep will be induced with dexmedetomidine, and interstitial fluid convection will be assessed by measuring free-water diffusion imaging. Freewater diffusion imaging separates out the contributions of extracellular free water and water in the vicinity of cellular tissue; it is used to evaluate abnormalities in extracellular space, such as neuroinflammation, which may contribute to long-term cellular degeneration. This method of analysis could be useful in assessing the lymph systems ability to remove extracellular debris.
The group in the trial
- DexmedetomidineTreatment being tested
All patients will complete neurocognitive testing inclusive of the Quick Dementia Rating Scale (QDRS) and Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)) to assess cognitive impairment. A Clinical Dementia Rating (CDR) score of 1 or above will be considered dementia. Lumbar punctures will be used to determine Alzheimer's disease status.The subjects will have three fMRI scans: structural T1 and two NOODI DTI scans. The dexmedetomidine will be given to the patient after the first DTI scan with a dosage that will be congruent with patient height, weight, and medical history.
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 28 September 2022